European consensus proposal for immunoglobulin therapies

Area of Science:

• Immunology
• Healthcare Management
• Pharmacoeconomics

Background:

• Global use of immunoglobulin (Ig) preparations (intravenous, IVIg, and subcutaneous, SCIg) has tripled in 20 years.
• This surge increases healthcare costs and relies heavily on human plasma collection.
• Rising diagnoses of primary immunodeficiencies and expanded immunomodulatory uses may lead to plasma supply shortages.

Purpose of the Study:

• To address the urgent need for consensus recommendations on optimal immunoglobulin (Ig) use.
• To establish priority rankings for the most critical Ig indications.
• To ensure sustainable access to essential Ig therapies.

Main Methods:

• A consensus meeting was held with expert nominees from 36 Council of Europe states.
• Colleagues from observer countries and regulatory agencies also participated.
• The outcome was a consensus statement outlining recommendations and priorities.

Main Results:

• Consensus was reached on the optimal utilization of Ig preparations.
• Priority indications for Ig therapy were identified and ranked.
• Recommendations aim to balance clinical need with plasma supply sustainability.

Conclusions:

• Optimal use of immunoglobulin (Ig) is crucial due to increased demand and limited supply.
• Consensus recommendations provide a framework for prioritizing Ig therapy.
• These guidelines support sustainable access to essential immunoglobulin treatments.